Intravenous Immunoglobulin (IVIg)

Global Market Trajectory & Analytics

MCP-7776

EXECUTIVE ENGAGEMENTS

POOL

1062
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

191
Interactions with Platform & by Email

PARTICIPANTS

42
Unique # Participated

VALIDATIONS

11
Responses Validated*

COMPANIES

24
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

168

PAGES

222

EDITION

17

PRICE

USD 5450

CODE

MCP-7776

COMPETITIVE METRICS

COMPANY
D S N T

% *

ADMA Biologics, Inc.

Bharat Serums and Vaccines Ltd.

Bio Products Laboratory Ltd.

Biotest AG

BriovaRx Infusion Services

China Biologic Products Holdings, Inc.

CSL Behring

CSL Ltd.

Emergent BioSolutions, Inc.

Evolve Biologics

*Login to Participate & View Data Stacks
View 24 Companies...

SUBMIT
Note: Best viewed in Landscape Mode
RESEARCH MODULES MARKET TRENDS EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Intravenous Immunoglobulin (IVIg) estimated at US$10.3 Billion in the year 2020, is projected to reach a revised size of US$15.7 Billion by 2027, growing at a CAGR of 6.2% over the analysis period 2020-2027. IgA, one of the segments analyzed in the report, is projected to record a 6.8% CAGR and reach US$5.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the IgD segment is readjusted to a revised 6% CAGR for the next 7-year period.
The Intravenous Immunoglobulin (IVIg) market in the U.S. is estimated at US$3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2027 trailing a CAGR of 5.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.9% and 4.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5% CAGR.
In the global IgE segment, USA, Canada, Japan, China and Europe will drive the 6.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.6 Billion in the year 2020 will reach a projected size of US$2.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.8 Billion by the year 2027.

SELECT PLAYERS

Bharat Serums and Vaccines Limited; Biotest AG; China Biologic Products, Inc.; CSL Limited; Grifols, S.A.; Hualan Biological Engineering Inc.; Kedrion S.p.A.; LFB Group; Octapharma AG; Shanghai RAAS Blood Products Co., Ltd.; Shire plc; Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

SEGMENTS

» Type (IgA, IgD, IgE, IgG, IgM) » Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications) » End-Use (Hospitals, Clinics, Homecare Settings) » Segment (Intravenous Immunoglobulin (IVIg))

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Immunoglobulins to See Steady Growth
Recent Market Activity
Intravenous Immunoglobulin - A Proliferating Biologic
Application Areas - A Brief Review
Market Outlook
Growth Drivers and Market Challenges
Competitive Scenario
Grifols Continues to Consolidate Market Position
CSL Sees Robust Growth in Immunoglobulin Franchise
Shire Continues to Invest Big in Immunoglobulins
Bivigam Changes Hands Consequent to Unexpected Turn of Events
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
Bharat Serums and Vaccines Limited (India)
Biotest AG (Germany)
China Biologic Products, Inc. (China)
Guizhou Taibang Biological Products Co., Ltd (China)
CSL Limited (Australia)
Grifols, S.A. (Spain)
Hualan Biological Engineering Inc. (China)
Kedrion S.p.A. (Italy)
LFB Group (France)
Octapharma AG (Switzerland)
Shanghai RAAS Blood Products Co., Ltd. (China)
Shire plc (Ireland)
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)
3. MARKET TRENDS & DRIVERS
Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth of Immunoglobulins
Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market
IVIg - The Mainstay of PI Therapy
Subcutaneous IG Formulations Gain Therapeutic Foothold
Hyperimmune Globulin - Taking IVIg Therapy a Step Ahead
Unsuccessful Clinical Trials for Alzheimer's - A major Setback for IVIg Market
Synthetic Replacements to IVIg Therapy
IVIg Therapy - Home-based vs. Outpatient Settings
Per Capita Consumption Rate Varies Across Countries
Favorable Reimbursement and High Usage make US the Largest Consumer
Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
Aging Global Population: Major Opportunity Indicator
Improving Healthcare Expenditure to Foster Growth
IV. COMPETITION
Total Companies Profiled: 24

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com